It was previously reported that constitutive RNASEH2A overexpression protected LNCaP prostate cancer cells against CPT or etoposide [34] and that RNase H2 depletion increased HU sensitivity in HeLa cells [15]. The gene discussed is RNASEH2A; the disease is prostate cancer.